Tuberculosis was formerly of interest to the nephrologist mainly as an occasional cause of renal insufficiency, unexplained hematuria or pyuria. It is now being observed with increasing frequency in dialysis units. This should come as no surprise in view of the reported T cell abnormalities in dialysis patients (1) , as well as the tendency of these patients to exhibit anergy to PPD and other delayed hypersensitivity substances.
T cell function plays an important role in the body's defense against primary tuberculosis. The initial infection probably occurs when an organism becomes implanted in an alveolus and subsequently spreads to the hilum. Within four to eight weeks macrophages are activated by T cells in order to confine the infection, at which time evidence of delayed hypersensitivity to tuberculin would be present. If the macrophage barrier breaks downs, the disease is reactivated; and if the focus breaks into the blood and embolizes, miliary tuberculosis ensues (2) . Tuberculosis is more frequent in malnourished or debilitated patients, in diabetes, and in the elderly, who according to a recent report may develop primary infection. Clearly then, the dialysis patient has several predisposing factors that may increase the risk of developing active tuberculosis. Yet diagnosis may be difficult because the symptoms tend to be attributed to other conditions.
Illustrating the high incidence of tuberculosis in certain dialysis populations is the report by Pradham et al (3) , who in 1974 reported a 15 times greater than expected incidence of tuberculosis in New York. Their patients presented with weight loss, fever, ascites, and pulmonary infiltrates, but the bacteriologic cultures were often negative. In another group of patients, mainly oriental, 4 out of 14 developed TB, and two of these were diabetic (1). The disease developed 18-24 months after initiating dialysis; fever and plural effusions were the usual presenting features, and the PPD was always negative.
Tuberculosis was discovered in 17 patients followed in a nephrology unit in the Southern United States, 9 of whom were on dialysis, the incidence being 1% (4). Of the patients 41 % hadextrapulmonary TB, but in those on dialysis 56% has spread outside the lungs. The PPD was usually negative, as were acid fast smears of the sputum, pleural fluid, and broncrial washings. The patients presented with symptoms of malaise, cough, and dyspnea. Biopsy was the most helpful test in establishing a diagnosis.
Another New York report (5) also demonstrated a tenfold greater than expected occurrence of tuberculosis in dialysis patients. Of these patients 88% had extrapulmonary disease. Only 3 of 8 patients developed the clinical disease early in the course of dialysis. Fever, anorexia and weight loss were the presenting symptoms, and 50% of the patients had ascites. Hepatomegally was present in an patients with extrapulmonary disease. Again, the diagnosis was often difficult to establish.
In contrast to these reports a study from San Francisco (6) found that most cases of TB occurred before or shortly after starting dialysis. The incidence was 12 times that expected, being unrelated to age or race. There was a high occurrence of extrapulmonary spread (40%), and 50% of patients had positive PPD. None had pulmonry cavities on x-ray, but all patients with pulmonary infiltrates had positive sputum cultures.
In a survey conducted in Japan, the incidence of TB was 3%, ten times the expected incidence (7) . One half of the patients had miliary TB, and they usually had gastrointestinal symptoms. Fever, weight loss, anorexia, mental abnormalities, high E.S.R. (over 100) and elevated C reactive protein were common. Early and prompt therapy reduced mortality from 4.8% to 0.9%. The patients developing miliary TB tended to be older (8) .
Because of a 3% incidence in his unit, Llorach believes that dialysis patients with unexplained pleural effusion (even transudate) should be considered for a 10 day trial of anti-tuberculosis therapy (9) .
Although most authors recommend using INH and rifampin, the role of triple therapy and the length of treatment in uremic patients is unclear. One recommendation (10) is two months of triple therapy (ethambutol as the third drug), followed by seven more months of INH and rifampin. The dosage of rifampin does not require alteration because it is excreted by the liver. In slow acetylators doses of INH may need to be reduced to 150 mgm daily and the blood level should be kept under 1 mgm% (11) .
Ethambutol must be used cautiously because it is excreted by the kidney. The recommended dose is 8-10 mgm/kg, and ideally blood levels should be measured and the patients should be monitored for changes in visual acuity and development of neuropathy, Since INH and ethambutol are dialyzable, they should be given after dialysis on the day of treatment.
The issue of prophylactic treatmetnt is even more controversial in dialysis patients than in the general population (12) . One group recommends (13) that all dialysis patients should have a PPD test, and if negative have another test for anergy. They would then advise INH treatment for all PPD positive patients not treated in the past, and close monitoring of the anergic patients.
In conclusion, as the number of elderly and diabetic dialysis patients continues to grow, tuberculosis may become more frequent and also more difficult to diagnose, often requiring tissue biopsy. Patients with constitutional symptoms, fever, high sedimentation rate, and hepatomegaly of unexplained cause should be considered for a therapeutic trial of anti-tuberculosis therapy. The need for prophylactic antituberculosis medication in hemodialysis patients requires further evaluation.
